cytotoxic T cell

(redirected from Cytotoxic T-lymphocyte)
Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.
Related to Cytotoxic T-lymphocyte: Killer T cells, CD8+ cell

cytotoxic T cell

The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

cytotoxic T cell

A CD8+ T lymphocyte that can destroy microorganisms directly through the release of perforin and proteolytic enzymes. These cells are particularly important in the defense against viruses, rejection of allografts, and, possibly, new malignant cells. Synonym: CD8 cell; cytotoxic cel; killer T cell
See also: cell
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
* The report reviews key players involved in Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics and enlists all their major and minor projects
Bagchi, "Induction of cytotoxic T-lymphocyte antigen-2[beta], a cysteine protease inhibitor in decidua: a potential regulator of embryo implantation," The Journal of Biological Chemistry, vol.
The in vitro tumor-specific cytotoxic T-lymphocyte (CTL) response elicited by immunization with mHSP/P was analyzed by means of lactate dehydrogenase release from damaged cells.
Yoshizawa et al., "Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients," Journal of Hepatology, vol.
AMSTERDAM -- The highly promising new class of investigational anticancer agents known at cytotoxic T-lymphocyte antigen 4 blockers has a characteristic group of side effects, Dr.
Computer-based design of an HLA-haplotype and HIV-clade independent cytotoxic T-lymphocyte assay for monitoring HIV-specific immunity.
Posttransplant lymphoproliferative disorder results from an expansion of the pool of Epstein-Barr virus (EBV)-infected B cells that are able to evade specific cytotoxic T-lymphocyte control, secondary to immunosuppressive therapy.
Oral and intranasal insulin appear to be promising approaches, he said, since animal studies suggest that insulin delivered to the mucosa induces insulin antibodies, which in turn reduce cytotoxic T-lymphocyte production.
Several immunosuppressive effects of EVs have also been reported [21, 32, 33]; for instance, Fas Ligand [(Fas-L).sup.+] EVs released from regulatory T cells are able to inhibit DC-induced cytotoxic T-lymphocyte (CTL) responses [21].
The results of a phase Ib/II study of T-VEC and ipilimumab, an anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) antibody have been reported.
Recent efforts have focused on the use of recombinant DNA techniques to stimulate cytotoxic T-lymphocyte responses.
While the study remains blinded, cytotoxic T-lymphocyte responses have been detected 16 of 116 volunteers, suggesting that the prime-boost approach may be appropriate for further clinical study.